# A Study of Tivozanib (AV-951), an Oral VEGF Receptor Tyrosine Kinase Inhibitor, in the Treatment of Renal Cell Carcinoma

> **NCT00502307** · PHASE2 · COMPLETED · sponsor: **AVEO Pharmaceuticals, Inc.** · enrollment: 272 (actual)

## Conditions studied

- Carcinoma, Renal Cell

## Interventions

- **DRUG:** Tivozanib (AV-951)
- **DRUG:** Placebo comparator

## Key facts

- **NCT ID:** NCT00502307
- **Lead sponsor:** AVEO Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-10
- **Primary completion:** 2010-08
- **Final completion:** 2010-08
- **Target enrollment:** 272 (ACTUAL)
- **Last updated:** 2020-09-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00502307

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00502307, "A Study of Tivozanib (AV-951), an Oral VEGF Receptor Tyrosine Kinase Inhibitor, in the Treatment of Renal Cell Carcinoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00502307. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*